Kawakami, H., Yuki, S., Kawabata, R., Sato, S., Ooki, A., Tsuji, K., Kawakami, T., Yamaguchi, T., Oda, H., Yoshida, T., Harada, K., Kubota, Y., Pak, K., Kakeji, Y., Terashima, M., Baba, E., Muro, K., Sunakawa, Y., Fujii, M., Ichikawa, W. (2026). Safety run-in results from C-SOLVE (JACCRO GC-12): A randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in patients with HER2-negative, CLDN18.2-positive unresectable advanced gastric or GEJ cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.352